Abstract
Trojanisches Aptamer: Eine neuartige Strategie für den gezielten Transport von Wirkstoffen zu Krebszellen beruht auf der Bildung eines physikalischen Konjugats (siehe Schema) zwischen Doxorubicin (Dox) und dem A10-RNA-Aptamer, das an das Prostata-spezifische Membranantigen (PSMA) bindet. Das Aptamer-Dox-Konjugat band effizient an PSMA-exprimierende Zellen; dabei wurde das Aptamer in die Zelle aufgenommen und schließlich Dox intrazellulär freigesetzt. Supporting information for this article is available on the WWW under http://www.wiley-vch.de/contents/jc_2001/2006/z602251_s.pdf or from the author. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
